dal-GenE Phase 3 Cardiovascular Precision Medicine Outcomes Trial Results Published in European Heart Journal
Trial was negatively impacted by the COVID-19 pandemic and did not meet the primary endpoint. However, the results validate the...
Pharmaceutical
Amryt to Report Q2 2022 Results on August 4, 2022
DUBLIN, Ireland, and Boston MA, July 21, 2022, Amryt (Nasdaq: AMYT) a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing...
IsoPlexis to Report Second Quarter 2022 Financial Results on August 10, 2022
BRANFORD, Conn., July 21, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today announced it will...
Newly Issued European Patent Broadens IN8bio’s Drug Resistant Immunotherapy (DRI) Platform
European patent covers any genetic modification conveying chemotherapy resistance to immune cell types, including gamma-delta T cells and now natural...
Zynerba Pharmaceuticals Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital
DEVON, Pa., July 21, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid...
Skye Bioscience Selects NextPharma as Phase 2 Contract Drug Manufacturer
Skye advances Phase 2 clinical development plans alongside Phase 1 clinical development San Diego, California, July 21, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience,...
Junshi Biosciences Receives Orphan Medicinal Product Designation from the European Committee for Toripalimab in Treatment of Nasopharyngeal Carcinoma
--6th Orphan Drug Designation granted to toripalimab in the US and EU SHANGHAI, China, July 21, 2022 (GLOBE NEWSWIRE) --...
ITM Signs Clinical Supply Agreement with Y-mAbs for n.c.a. Lutetium-177
ITM to supply its medical radioisotope, no-carrier-added Lutetium-177, for the clinical development of Y-mAbs’ Targeted Radionuclide Therapy candidate GD2-SADA: 177Lu-DOTA...
Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF)
Submission supported by comprehensive analytical data package and clinical Phase I pharmacokinetics bridging study Proposed Hyrimoz® HCF would help expand...
[Ad hoc announcement pursuant to Art. 53 LR] Roche: Change in the Board of Directors and Corporate Executive Committee in Spring 2023
Christoph Franz has decided not to seek re-election to the Board of Directors at the Annual General Meeting (AGM) in...
Addex Completes Reduction in Nominal Value of Shares
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 21, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN),...
Addex Provides Corporate Update and Financial Guidance
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 21, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN),...
[Ad hoc announcement pursuant to Art. 53 LR] Roche achieves good results in the first six months of 2022
Basel, 21 July 2022 Group sales up 5%1 at constant exchange rates (CER) and 5% in Swiss francsPharmaceuticals Division sales...
G1 Therapeutics to Release Second Quarter 2022 Financial Results and Provide Business Update on August 3, 2022
RESEARCH TRIANGLE PARK, N.C., July 20, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will...
FDA Approves QSYMIA® for the Treatment of Obesity in Adolescents Ages 12-17
CAMPBELL, Calif., July 20, 2022 (GLOBE NEWSWIRE) -- VIVUS LLC today announced that the U.S. Food and Drug Administration (FDA)...
Altamira Therapeutic’s SemaPhore Platform Shown Particularly Effective in Intracellular mRNA Delivery for Cancer Therapy
Peer-reviewed study highlights high potential for cell-penetrating peptides in mRNA-based cancer treatmentsDemonstrates effective uptake and transfection capacity of Altamira’s proprietary...
Novan Satisfies $16.5 Million Outstanding Promissory Note
– Novan and Evening Post Group enter into a loan payoff and termination agreement, fully satisfying the promissory note and...
Celsion Appoints Dr. Corinne Le Goff as President and Chief Executive Officer
Michael H. Tardugno appointed Executive Chairman of the Board LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN),...
COMPASS Pathways appoints Kabir Nath as Chief Executive Officer
Kabir Nath will build upon COMPASS’ success and lead the development of novel models of care to accelerate patient access...
HTG Molecular Diagnostics Hosting a KOL Event Addressing Drug Candidate Attrition
TUCSON, Ariz., July 19, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing...